☆ 4.3 Meeting Abstract

Characterising properties of dimethylfumarate on innate and adaptive immunity: longitudinal data from MS patients

MULTIPLE SCLEROSIS JOURNAL (2017)

Add to Collection

Journal

MULTIPLE SCLEROSIS JOURNAL
Volume 23, Issue -, Pages 872-873

Publisher

SAGE PUBLICATIONS LTD

Keywords

-

Categories

Clinical Neurology Neurosciences

Funding

  1. Biogen
  2. Novartis Pharma
  3. Merck Serono
  4. Teva
  5. Bayer-Schering
  6. GeNeuro
  7. Mitsubishi Pharma
  8. MedDay
  9. Roche
  10. Genzyme
  11. Swiss MS Society
  12. Swiss National Science Foundation
  13. European FP6 program
  14. IMI JU program
  15. Roche Postdoc Fellowship Program (RPF-program)
  16. Novartis
  17. Actelion
  18. Addex
  19. Bayer HealthCare
  20. Biotica
  21. Lilly
  22. Merck
  23. Mitsubishi
  24. Ono
  25. Pfizer
  26. Receptos
  27. Sanofi-Aventis
  28. Santhera
  29. Siemens
  30. UCB
  31. Xenoport
  32. CSL Behring
  33. European Union
  34. Roche Research Foundations
  35. Swiss Multiple Sclerosis Society
  36. Swiss National Research Foundation

Ask authors/readers for more resources

Protocol

Community support

Reagent

Community support

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.3
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available
Webinars Posters Questions Hubs Funding Journals Papers Connect Collections Reviewers About Us FAQs Mobile App Privacy Policy Terms of Use
© Peeref 2019-2024. All rights reserved.